SEOUL, South Korea – Promising as the biosimilar market appears today, a consolidation that leaves only a handful of global players may be inevitable and the prospects may not be as rosy as they seem, said drug company executives at Bio Korea 2014. Read More
Two separate draft catalogs of the human proteome have brought new insights into the relationship between genes and proteins, identifying both proteins that were transcribed from supposedly noncoding regions of the genome, and genes that never got turned into proteins even though they had all the bells and whistles that flag them as bona fide protein-coding genes. Read More
It's time to raise the bar for requiring makers of drugs and vaccines to create pregnancy exposure registries, the FDA was told Wednesday at a public meeting on postapproval evaluation of drug safety during pregnancy. Read More
While big pharma firms are expected to make the big splash in immuno-oncology at the upcoming American Society of Clinical Oncology (ASCO) meeting, small biotech Armo Biosciences Inc. also will be on hand with a poster on AM0010, a promising interleukin-10 (IL-10)-targeting immunotherapy that helped the Redwood City, Calif.-based firm attract $30 million in series B funding. Read More
SHANGHAI – Glaxosmithkline plc has confirmed the company is under investigation by the UK Serious Fraud Office (SFO). The case is presumed to be related to the almost year-long corruption investigation into GSK China activities that came to a close last week. Read More
Chimerix Inc., of Durham, N.C., said it completed an underwritten public offering of about 8.4 million shares of its common stock, which included approximately 1.1 million shares sold by the underwriters who exercised their option to purchase additional shares at the offering price of $14.22 per share. Read More
Intensity Therapeutics Inc., of Westport, Conn., established a cooperative research and development agreement, with the National Cancer Institute to study the efficacy and mechanism of action of its NKT cell agonist-based in situ chemo-vaccination products using in vivo models of cancer. Read More
Boehringer Ingelheim AG (BI), of Ingelheim, Germany, reached a comprehensive settlement of state and federal cases in the U.S. litigation regarding the anticoagulant Pradaxa (dabigatran etexilate mesylate) in the amount of $650 million. Read More
